38716 Federal Register / Vol. 83, No. 152 / Tuesday, August 7, 2018 / Notices 

Wednesday, September 19, 2018 will be 

presented to the working group prior to 

the workshop. Any written comments 

received after the 5:00 p.m. ET, 

Wednesday, September 19, 2018 

deadline through Tuesday, September 

25, 2018 will be provided to the 

working group either before or after the 

meeting, depending on the volume of 

comments received and the time 

required to process them in accordance 

with privacy regulations and other 

applicable Federal policies. All written 

public comments and oral public 

comment statements received by the 

deadlines for both oral and written 

public comments will be provided to 

the IACC for their consideration and 

will become part of the public record. 

Attachments of copyrighted 

publications are not permitted, but web 

links or citations for any copyrighted 

works cited may be provided. 

In the 2009 IACC Strategic Plan, the 

IACC listed the ‘‘Spirit of Collaboration’’ 

as one of its core values, stating that, 

‘‘We will treat others with respect, listen 

to diverse views with open minds, 

discuss submitted public comments, 

and foster discussions where 

participants can comfortably offer 

opposing opinions.’’ In keeping with 

this core value, the IACC and the NIMH 

Office of Autism Research Coordination 

(OARC) ask that members of the public 

who provide public comments or 

participate in meetings of the IACC also 

seek to treat others with respect and 

consideration in their communications 

and actions, even when discussing 

issues of genuine concern or 

disagreement. 

Remote Access: The meeting will be 

open to the public through a conference 

call phone number and webcast live on 

the internet. Members of the public who 

participate using the conference call 

phone number will be able to listen to 

the meeting but will not be heard. If you 

experience any technical problems with 

the webcast or conference call, please 

send an e- mail to IACCPublicInquiries@

mail.nih.gov. Individuals wishing to 

participate in person or by using these 

electronic services and who need 

special assistance, such as captioning of 

the conference call or other reasonable 

accommodations, should submit a 

request to the Contact Person listed on 

this notice at least 5 days prior to the 

meeting. 

Special Accommodations: Individuals 

who participate in person or by using 

these electronic services and who need 

special assistance, such as captioning of 

the conference call or other reasonable 

accommodations, should submit a 

request to the Contact Person listed on 

this notice at least 5 days prior to the 

meeting. 

Security: Visitors will be asked to 

show one form of identification (for 

example, a government-issued photo ID, 

driver’s license, or passport) and to state 

the purpose of their visit. Also, as a part 

of security procedures, attendees should 

be prepared to present a photo ID at the 

meeting registration desk during the 

check-in process. Pre-registration is 

recommended. Seating will be limited 

to the room capacity and seats will be 

on a first come, first serve basis, with 

expedited check-in for those who are 

pre-registered. 

Meeting schedule subject to change. 

Information about the IACC is available 

on the website: http://www.iacc.hhs.gov. 

Dated: August 1, 2018. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–16793 Filed 8–6–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Initial Review Group, Biological Aging 

Review Committee NIA–B. 

Date: September 27–28, 2018. 

Time: 2:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Rd., Bethesda, MD 20814 (Telephone 

Conference Call). 

Contact Person: Bita Nakhai, Ph.D., 

Scientific Review Branch, National Institute 

on Aging, Gateway Bldg., 2C212, 7201 

Wisconsin Avenue, Bethesda, MD 20814, 

301–402–7701, nakhaib@nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: August 1, 2018. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–16788 Filed 8–6–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Vince Contreras, Ph.D., 240–669–2823; 

vince.contreras@nih.gov. Licensing 

information and copies of the U.S. 

patent application listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Substitutions-Modified Prefusion RSV F 

Proteins and Their Use 

Description of Technology: The 

respiratory syncytial virus (RSV) fusion 

(F) glycoprotein is the primary target of 

neutralizing antibodies. The F 

glycoprotein exists in at least two 

conformations, a meta-stable prefusion 

state, and an extremely stable postfusion 

state. Both states share several epitopes 

targeted by neutralizing antibodies, but 

it has been demonstrated that the 

prefusion conformation of F contains at 

least one epitope not present in the 

postfusion conformation. Natural 

infection results in neutralizing 

antibodies that are primarily directed 

against the prefusion conformation of F, 

not its postfusion conformation. The 

instability of the prefusion form of F has 


daltland on DSKBBV9HB2PROD with NOTICES